Data gathered: April 15
Alternative Data for Lineage Cell Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,245 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 59 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,236 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,231 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 33 | Sign up | Sign up | Sign up |
About Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally.
| Price | $0.44 |
| Target Price | Sign up |
| Volume | 969,580 |
| Market Cap | $107M |
| Year Range | $0.39 - $0.95 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Lineage Cell Therapeutics : Wave Life Sciences Announces Positive Data from FORWARD 53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE N531March 26 - Finnhub |
|
 |
B. Riley Predicts Lineage Cell Therapeutics Q1 EarningsMarch 17 - ETF Daily News |
 |
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Lowered to $3.00 at B. RileyMarch 16 - ETF Daily News |
|
HC Wainwright Forecasts Lineage Cell Therapeutics Q1 EarningsMarch 14 - ETF Daily News |
|
HC Wainwright Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)March 12 - ETF Daily News |
|
D. Boral Capital Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)March 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 3.8M | 38,000 | 3.7M | -3M | -3.7M | -0.020 |
| Q2 '24 | 1.4M | 44,000 | 1.4M | -5.8M | -5.7M | -0.030 |
| Q1 '24 | 1.4M | 98,000 | 1.3M | -6.5M | -6.5M | -0.040 |
| Q4 '23 | 2.1M | 260,000 | 1.8M | -4.8M | -425M | -0.030 |
| Q3 '23 | 1.2M | 170,000 | 1.1M | -7.1M | 136M | -0.040 |
Insider Transactions View All
| BROADWOOD PARTNERS, L.P. filed to buy 7,894,737 shares at $0. January 28 '25 |
| BROADWOOD PARTNERS, L.P. filed to buy 7,894,737 shares at $0. January 28 '25 |
| Samuel George A. III filed to buy 22,184 shares at $0.6. November 26 '24 |
| Howe Jill Ann filed to buy 25,500 shares at $0.6. November 26 '24 |
| Mulroy Michael H. filed to buy 298,555 shares at $0.6. November 25 '24 |
Similar companies
Read more about Lineage Cell Therapeutics (LCTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Lineage Cell Therapeutics?
The Market Cap of Lineage Cell Therapeutics is $107M.
What is the current stock price of Lineage Cell Therapeutics?
Currently, the price of one share of Lineage Cell Therapeutics stock is $0.44.
How can I analyze the LCTX stock price chart for investment decisions?
The LCTX stock price chart above provides a comprehensive visual representation of Lineage Cell Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lineage Cell Therapeutics shares. Our platform offers an up-to-date LCTX stock price chart, along with technical data analysis and alternative data insights.
Does LCTX offer dividends to its shareholders?
As of our latest update, Lineage Cell Therapeutics (LCTX) does not offer dividends to its shareholders. Investors interested in Lineage Cell Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Lineage Cell Therapeutics?
Some of the similar stocks of Lineage Cell Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.